Publications

Journal Article
Research Support, Non-U.S. Gov't
Ppublish 52 citations
Electronic publication date
September 25, 2009

View on Pubmed.gov 19639200 | View on doi.org 10.3892/or_0000...

The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer.

Search for publications in this journal Oncol Rep - 22(3):535-9

Abstract

High-mobility group protein box 1 (HMGB1) released from dying tumor cells promotes tumor progression, on the other hand HMGB1 activates dendritic cells and triggers anti-neoplastic response of T-cells in chemotherapy and radiotherapy. HMGB1 expression is up-regulated in many kinds of tumors. To investigate HMGB1 expression in non-small cell lung cancer, 63 patients were enrolled and tumor tissues were collected with matched normal lung tissues. HMGB1 mRNA and protein levels were quantified with real-time PCR, Western blots and immunohistochemistry. The HMGB1 expression in tumor tissue was lower than in matched normal lung tissue at mRNA levels (Paired t-test, t<0.001) and the down-regulation in stage III-IV patients was also significantly greater than one in stage I-II (one-way ANOVA, p=0.005). At protein level, HMGB1 expression was also down-regulated. Low HMGB1 expression in non-small cell lung cancer may explain the poor therapeutical outcome during chemotherapy and radiotherapy.

References

No references provided.

Cited by 52 citations (total)

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma.

Electronic publication date October 25, 2011

Search for publications in this journal J Proteome Res

Jintao Zhang [...] Jian-Ying Zhang et al.

Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers in China. The lower survival rate of ESCC...

Journal Article Research Support, Non-U.S. Gov't

Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.

Electronic publication date July 30, 2014

Search for publications in this journal Cell Death Differ

T Yamazaki [...] L Zitvogel et al.

Immunogenic cell death induced by anticancer chemotherapy is characterized by a series of molecular hallmarks that include the exodus of...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances